AMR ACCELERATOR

Global awareness of the severity of the problem is urgently needed, and important actors, such as the World Health Organisation (WHO) have already set up large campaigns in order to raise public awareness. The Innovative Medicines Initiative (IMI) has invested heavily in combating AMR, and the AMR Accelerator Programme complements and builds on the achievements of IMI's New Drugs for Bad Bugs Programme, which also focuses on AMR. We recommend to navigate through the Incentives Gallery of the Global AMR R&D Hub to find out about the other initiatives in place around the world that aim to improve the R&D ecosystem committed to developing and distributing therapeutics for treating priority, human, bacterial infections... The AMR Accelerator aims to deliver 10 preclinical or clinical candidates and 5 Phase II or III-ready assets... AMR represents a serious and growing threat to human and animal health worldwide. A number of infections, such as pneumonia, tuberculosis and gonorrhoea, are..

Registration numbers: HRB 68816 (W)

VAT numbers: DE 136767144

Primary location: Berlin Germany